Trial site
the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,
Shanghai, Shanghai Municipality 200011, ChinaNot linked to an institution yet
- 11running trials
- 3closed trials
The trials here
What the 14 trials at this site are about, from their registry records.
- Phase
- Phase 211 trials
- Phase 1/21 trial
- Phase 31 trial
- Status
- Recruiting9 trials
- Completed3 trials
- Active, not recruiting1 trial
- Not yet recruiting1 trial
- Lead sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University13 trials
- Bio-Thera Solutions1 trial
Running trials
Recruiting
Zemetostat With Anlotinib in Patients With Recurrent/Metastatic Head and Neck Soft Tissue Sarcoma
NCT07917949· Phase 2· Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University· Source
Contact: Guoxin Ren, M.D.
Recruiting
Iparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCC
NCT07882888· Phase 2· Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University· Source
Contact: Guoxin Ren, M.D.
Recruiting
Efficacy and Safety of Paclitaxel Polymeric Micelles in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT07662746· Phase 2· Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University· Source
Contact: Guoxin Ren, M.D.
Recruiting
Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies
NCT07662681· Phase 1/2· Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University· Source
Contact: Guoxin Ren, M.D.
Not yet recruiting
CLASSIFY-OMM: Multicenter Rare Disease Cohort for T-Stage Reclassification and Molecular Subtyping-Based Precision Therapy in Oral Mucosal Melanoma
NCT07662694· Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University· Source
Contact: Guoxin REN MD, MD
Recruiting
Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma
NCT07632339· Phase 2· Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University· Source
Contact: Guoxin Ren, M.D.
Recruiting
Iparomlimab and Tuvonralimab in HNSCC
NCT07090317· Phase 2· Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University· Source
Contact: Guoxin Ren, M.D.
Recruiting
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
NCT07088211· Phase 2· Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University· Source
Contact: Guoxin Ren
Recruiting
Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
NCT06935188· Phase 2· Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University· Source
Contact: Guoxin Ren, M.D.
Recruiting
Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma
NCT06470217· Phase 2· Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University· Source
Contact: Yanan Wang, M.D.
Active, not recruiting
Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study
NCT05586100· Phase 2· Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error